Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, November 05, 2015
Mylan has announced that the U.S. Federal Trade Commission has cleared the company's proposed transaction to acquire Perrigo Company subject to Mylan's divestiture of certain products following the consummation of the offer.
read more
Thursday, November 05, 2015
Precision for Value has acquired Redwood Outcomes, an international health economics and outcomes research (HEOR) company.
read more
Thursday, November 05, 2015
The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by ...
read more
Wednesday, November 04, 2015
Bristol-Myers Squibb has entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
read more
Tuesday, November 03, 2015
Catalent has announced that Dr. Donald E. Morel will be added to its Board of Directors, effective the next time the Board convenes, increasing the size of the Board to ten members.
read more
Tuesday, November 03, 2015
Cytovance Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a ...
read more
Tuesday, November 03, 2015
PharPoint Research, Inc., a contract research organization (CRO), has announced that the stable growth of new employees has led to the expansion of their Wilmington, NC office.
read more
Tuesday, November 03, 2015
Moberg Pharma AB has announced that Moberg Pharma and Colep have entered a Development Agreement for MOB-015 – a novel topical formulation of terbinafine for onychomycosis (nail fungus).
read more
Monday, November 02, 2015
CluePoints today announced a strategic collaboration with clinical trials business solutions consultancy, Widler & Schiemann Ltd. The collaboration will bring together CluePoints' award-winning RBM software with Widler & Schiemann's risk-assessment ...
read more
Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability...
read more
Halozyme Therapeutics has announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics...
read more
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management ...
read more
Gilead Sciences and WuXi PharmaTech have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
read more
The collaboration will utilize Affinivax’s proprietary vaccine platform, Multiple Antigen Presentation System (MAPS), to develop vaccines to prevent bacterial nosocomial infections, also referred to as health-care associated infections (HAIs).
read more
Charleston Laboratories and Daiichi Sankyo have announced that a third Phase 3 clinical trial of CL-108, an opioid-containing formulation, met its primary endpoints.
read more